Bank of America’s Cellectar Biosciences CLRB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-36
Closed -$106 5944
2025
Q4
$106 Buy
36
+9
+33% +$33 ﹤0.01% 6809
2025
Q3
$152 Buy
27
+25
+1,250% +$124 ﹤0.01% 7775
2025
Q2
$14 Sell
2
-10
-83% -$87 ﹤0.01% 8274
2025
Q1
$109 Sell
12
-6,881
-100% -$62.3K ﹤0.01% 7812
2024
Q4
$61.8K Buy
6,893
+1,390
+25% +$64.3K ﹤0.01% 6567
2024
Q3
$353K Buy
5,503
+3,401
+162% +$224K ﹤0.01% 5704
2024
Q2
$158K Buy
2,102
+1,456
+225% +$140K ﹤0.01% 6016
2024
Q1
$77.2K Buy
646
+645
+64,500% +$69.9K ﹤0.01% 6369
2023
Q4
$44 Buy
+1
New +$74 ﹤0.01% 7514
2023
Q1
Sell
-1
Closed -$34 7852
2022
Q4
$34 Buy
+1
New +$60 ﹤0.01% 7869
2022
Q3
Sell
-5
Closed -$1K 7872
2022
Q2
$1K Buy
+5
New +$714 ﹤0.01% 7850
2022
Q1
Hold
0
8302
2021
Q4
Hold
0
8255
2021
Q3
Hold
0
8131
2021
Q2
Hold
0
7781
2020
Q2
Sell
-5
Closed -$2K 6849
2020
Q1
$2K Buy
+5
New +$3.35K ﹤0.01% 6623
2019
Q4
Hold
0
7110
2019
Q3
Hold
0
7273
2019
Q2
Hold
0
7201
2019
Q1
Hold
0
7136
2018
Q4
Sell
-1
Closed -$712 7134
2018
Q3
$1K Buy
+1
New +$1.18K ﹤0.01% 7110
2016
Q4
Hold
0
7065
2016
Q3
Hold
0
7126
2016
Q1
Hold
0
-$1K 7034
2015
Q4
Hold
0
7181
2015
Q3
Hold
0
6956
2015
Q2
Hold
0
6954
2015
Q1
Hold
0
6621
2014
Q4
Hold
0
7392

Other funds holding CLRB

Bank of America's CLRB Position: Q1 2026 in Review

Bank of America sold out of Cellectar Biosciences (CLRB) in Q1 2026, closing a stake of 36 shares — an estimated $106 sold.

Bank of America first reported a position in CLRB in Q3 2018 and held it in 13 quarters. The position peaked at $353K in Q3 2024. 19 funds tracked by Wall St. Rank hold CLRB as of Q1 2026.

  • Bank of America reported no remaining Cellectar Biosciences position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 36 Cellectar Biosciences shares in Q1 2026, an estimated $106.
  • Bank of America first reported a position in Cellectar Biosciences in Q3 2018 and held it in 13 quarters.
  • Bank of America's Cellectar Biosciences position peaked at $353K in Q3 2024.
  • 19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.